Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.

Jaffré F, Miller CL, Schänzer A, Evans T, Roberts AE, Hahn A, Kontaridis MI.

Circulation. 2019 Jul 16;140(3):207-224. doi: 10.1161/CIRCULATIONAHA.118.037227. Epub 2019 Jun 5.

PMID:
31163979
2.

Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene.

Li R, Baskfield A, Lin Y, Beers J, Zou J, Liu C, Jaffré F, Roberts AE, Ottinger EA, Kontaridis MI, Zheng W.

Stem Cell Res. 2019 Jan;34:101374. doi: 10.1016/j.scr.2018.101374. Epub 2018 Dec 26.

3.

Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.

Zheng H, Yu WM, Waclaw RR, Kontaridis MI, Neel BG, Qu CK.

Sci Signal. 2018 Mar 20;11(522). pii: eaao1591. doi: 10.1126/scisignal.aao1591.

4.

Physiology of Cardiac Development: From Genetics to Signaling to Therapeutic Strategies.

Sun C, Kontaridis MI.

Curr Opin Physiol. 2018 Feb;1:123-139. doi: 10.1016/j.cophys.2017.09.002. Epub 2017 Dec 13.

5.

In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.

Wang J, Chandrasekhar V, Abbadessa G, Yu Y, Schwartz B, Kontaridis MI.

PLoS One. 2017 Jun 5;12(6):e0178905. doi: 10.1371/journal.pone.0178905. eCollection 2017.

6.

DDiT4L promotes autophagy and inhibits pathological cardiac hypertrophy in response to stress.

Simonson B, Subramanya V, Chan MC, Zhang A, Franchino H, Ottaviano F, Mishra MK, Knight AC, Hunt D, Ghiran I, Khurana TS, Kontaridis MI, Rosenzweig A, Das S.

Sci Signal. 2017 Feb 28;10(468). pii: eaaf5967. doi: 10.1126/scisignal.aaf5967.

7.

Metformin protects against infection-induced myocardial dysfunction.

Tzanavari T, Varela A, Theocharis S, Ninou E, Kapelouzou A, Cokkinos DV, Kontaridis MI, Karalis KP.

Metabolism. 2016 Oct;65(10):1447-58. doi: 10.1016/j.metabol.2016.06.012. Epub 2016 Jul 9.

8.

Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.

Lauriol J, Cabrera JR, Roy A, Keith K, Hough SM, Damilano F, Wang B, Segarra GC, Flessa ME, Miller LE, Das S, Bronson R, Lee KH, Kontaridis MI.

J Clin Invest. 2016 Aug 1;126(8):2989-3005. doi: 10.1172/JCI80396. Epub 2016 Jun 27.

9.

Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus.

Wang J, Mizui M, Zeng LF, Bronson R, Finnell M, Terhorst C, Kyttaris VC, Tsokos GC, Zhang ZY, Kontaridis MI.

J Clin Invest. 2016 Jun 1;126(6):2077-92. doi: 10.1172/JCI87037. Epub 2016 May 16.

10.

A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.

Breitkopf SB, Yang X, Begley MJ, Kulkarni M, Chiu YH, Turke AB, Lauriol J, Yuan M, Qi J, Engelman JA, Hong P, Kontaridis MI, Cantley LC, Perrimon N, Asara JM.

Sci Rep. 2016 Feb 3;6:20471. doi: 10.1038/srep20471.

11.

Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog.

Hahn A, Lauriol J, Thul J, Behnke-Hall K, Logeswaran T, Schänzer A, Böğürcü N, Garvalov BK, Zenker M, Gelb BD, von Gerlach S, Kandolf R, Kontaridis MI, Schranz D.

Am J Med Genet A. 2015 Apr;167A(4):744-51. doi: 10.1002/ajmg.a.36982. Epub 2015 Feb 23.

12.

RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis.

Lauriol J, Keith K, Jaffré F, Couvillon A, Saci A, Goonasekera SA, McCarthy JR, Kessinger CW, Wang J, Ke Q, Kang PM, Molkentin JD, Carpenter C, Kontaridis MI.

Sci Signal. 2014 Oct 21;7(348):ra100. doi: 10.1126/scisignal.2005262.

13.

The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease.

Lauriol J, Jaffré F, Kontaridis MI.

Semin Cell Dev Biol. 2015 Jan;37:73-81. doi: 10.1016/j.semcdb.2014.09.013. Epub 2014 Sep 22. Review.

14.

PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.

Paardekooper Overman J, Yi JS, Bonetti M, Soulsby M, Preisinger C, Stokes MP, Hui L, Silva JC, Overvoorde J, Giansanti P, Heck AJ, Kontaridis MI, den Hertog J, Bennett AM.

Mol Cell Biol. 2014 Aug;34(15):2874-89. doi: 10.1128/MCB.00135-14. Epub 2014 May 27.

15.

How to get a K award: it is not just about the science.

Kontaridis MI.

Circ Res. 2014 Mar 14;114(6):941-3. doi: 10.1161/CIRCRESAHA.113.302994. No abstract available.

16.

Cardiomyocyte ATP release through pannexin 1 aids in early fibroblast activation.

Dolmatova E, Spagnol G, Boassa D, Baum JR, Keith K, Ambrosi C, Kontaridis MI, Sorgen PL, Sosinsky GE, Duffy HS.

Am J Physiol Heart Circ Physiol. 2012 Nov 15;303(10):H1208-18. doi: 10.1152/ajpheart.00251.2012. Epub 2012 Sep 14.

17.

PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?

Lauriol J, Kontaridis MI.

Trends Cardiovasc Med. 2011 May;21(4):97-104. doi: 10.1016/j.tcm.2012.03.006. Review.

18.

Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, Wu X, Lauriol J, Wang B, Bauer M, Bronson R, Franchini KG, Neel BG, Kontaridis MI.

J Clin Invest. 2011 Mar;121(3):1026-43. doi: 10.1172/JCI44972. Epub 2011 Feb 21.

19.

Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.

Stewart RA, Sanda T, Widlund HR, Zhu S, Swanson KD, Hurley AD, Bentires-Alj M, Fisher DE, Kontaridis MI, Look AT, Neel BG.

Dev Cell. 2010 May 18;18(5):750-62. doi: 10.1016/j.devcel.2010.03.009.

20.

Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.

Kontaridis MI, Yang W, Bence KK, Cullen D, Wang B, Bodyak N, Ke Q, Hinek A, Kang PM, Liao R, Neel BG.

Circulation. 2008 Mar 18;117(11):1423-35. doi: 10.1161/CIRCULATIONAHA.107.728865. Epub 2008 Mar 3. Erratum in: Circulation.2008 Apr 15;117(15) e314.

21.

Stops along the RAS pathway in human genetic disease.

Bentires-Alj M, Kontaridis MI, Neel BG.

Nat Med. 2006 Mar;12(3):283-5. No abstract available.

PMID:
16520774
22.

PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.

Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG.

J Biol Chem. 2006 Mar 10;281(10):6785-92. Epub 2005 Dec 23.

23.

Resveratrol inhibits angiotensin II- and epidermal growth factor-mediated Akt activation: role of Gab1 and Shp2.

Haider UG, Roos TU, Kontaridis MI, Neel BG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM.

Mol Pharmacol. 2005 Jul;68(1):41-8. Epub 2005 Apr 22.

PMID:
15849355
24.

SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway.

Kontaridis MI, Eminaga S, Fornaro M, Zito CI, Sordella R, Settleman J, Bennett AM.

Mol Cell Biol. 2004 Jun;24(12):5340-52.

25.

SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis.

Ivins Zito C, Kontaridis MI, Fornaro M, Feng GS, Bennett AM.

J Cell Physiol. 2004 May;199(2):227-36.

PMID:
15040005
26.

Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.

Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG.

Mol Cell. 2004 Feb 13;13(3):341-55.

27.

Role of SHP-2 in fibroblast growth factor receptor-mediated suppression of myogenesis in C2C12 myoblasts.

Kontaridis MI, Liu X, Zhang L, Bennett AM.

Mol Cell Biol. 2002 Jun;22(11):3875-91.

28.

SHP-2 complex formation with the SHP-2 substrate-1 during C2C12 myogenesis.

Kontaridis MI, Liu X, Zhang L, Bennett AM.

J Cell Sci. 2001 Jun;114(Pt 11):2187-98.

29.

Arginine-enhanced enteral nutrition augments the growth of a nitric oxide-producing tumor.

Edwards PD, Topping D, Kontaridis MI, Moldawer LL, Copeland EM 3rd, Lind DS.

JPEN J Parenter Enteral Nutr. 1997 Jul-Aug;21(4):215-9.

PMID:
9252947
30.

Nitric oxide contributes to adriamycin's antitumor effect.

Lind DS, Kontaridis MI, Edwards PD, Josephs MD, Moldawer LL, Copeland EM 3rd.

J Surg Res. 1997 May;69(2):283-7.

PMID:
9224394

Supplemental Content

Loading ...
Support Center